The Efficacy and Safety of the Combination Therapy of Daratumumab, Cabozantinib, Pomalidomide, and Dexamethasone (D-KPd) in the Treatment of High-risk First-time Relapsed or Primary Refractory MM Patients

NCT07015021 · clinicaltrials.gov ↗

NA

Phase

NOT_YET_RECRUITING

Status

72

Enrollment

OTHER

Sponsor class

Conditions

Multiple Myeloma
Carfilzomib
Daratumumab
Pomalidomide

Interventions

DRUG: Daratumumab
DRUG: Cafizomide
DRUG: Pomalidomide
DRUG: Dexamethasone

Sponsor

The First Affiliated Hospital of Soochow University